Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

Nature Genetics

Volumn 13, Issue 2, 1996, Pages 233-237

  Naski, Michael C ^a   Wang, Qing ^a   Xu, Jingsong ^a   Ornitz, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR;

ACHONDROPLASIA; ANIMAL CELL; ARTICLE; BONE GROWTH; CELL PROLIFERATION; ENCHONDRAL OSSIFICATION; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THANATOPHORIC DWARFISM;

3T3 CELLS; ACHONDROPLASIA; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL DIVISION; GENE EXPRESSION REGULATION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEINS; THANATOPHORIC DYSPLASIA; TRANSFECTION;

EID: 0029935895     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng0696-233     Document Type: Article

References (30)

1. Oberklaid, F., Danks, D.M., Jensen, F., Stace, L. & Rosshandler, S. Achondroplasia and hypochondraplasia. Comments on frequencey, mutation rate, and radiological features in skull and spine. J. Med. Genet. 16, 140-146. (1979).
2. Briner, J., Giedion, A. & Spycher, M.A. Variation of quantitative and qualitative changes of enchondral ossification in heterozygous achondroplasia. Pathol. Res. Pract. 187, 271-278 (1991).
3. Shah, K., Astley, R. & Cameron, A.H. Thanatophoric dwarfism. J. Med. Genet. 10, 243-252. (1973).
4. Tavormina, P.L. et al. Thanatophonc dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet. 9, 321-328 (1995).
5. Rousseau, F. et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252-254 (1994).
6. Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335-342 (1994).
7. Rimoin, D.L. & Lachman, R.S. Genetic disorders of the osseous skeleton, in McKusick's Heritable Disorders of connective tissue. (ed. Beighton, P.) 557-689. (Mosby-Year Book, St. Louis, 1993).
8. Ornitz, D.M., Yayon, A., Flanagan, J.G., Svahn, C.M., Levi, E. & Leder, P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol. Cell. Biol. 12, 240-247 (1992).
9. Ornitz, D.M. & Leder, P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem. 267, 16305-16311 (1992).
10. Chellaiah, A.T., McEwen, D.G., Werner, S., Xu, J. & Ornitz, D.M. Fibroblast Growth Factor Receptor (FGFR) 3: Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J. Biol. Chem. 269, 11620-11627 (1994).
11. Keegan, K., Meyer, S. & Hayman, M.J. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene 6, 2229-2236 (1991).
12. Bargmann, C.I., Hung, M.-C. & Weinberg, R.A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657 (1986).
13. Neilson, K.M. & Friesel, R.E. Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. J. Biol. Chem. 270, 26037-26040. (1995).
14. Santoro, M. et al. Activation of RET as a dominant transforming gene by germline mutatins of MEN2A and MEN2B. Science 267, 381-383. (1995).
15. Sorokin, A., Lemmon, M.A., Ullrich, A. & Schlessinger, J. Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond. J. Biol. Chem. 269, 9752-9759. (1994).
16. Watowich, S.S., Hilton, D.J. & Lodish, H.F. Activation and inhibition of erythrapoietin receptor function: Role of receptor dimerization. Mol. Cell. Biol. 14, 3535-3549. (1994).
17. Blechman, J.M. et al. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80, 103-113. (1995).
18. De Vos, A.M., Ultscyh, M. & Kossiakoff, A.A. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 255, 306-312. (1992).
19. Muenke, M. & Schell, U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends. Genet. 11, 308-313 (1995).
20. Wilkie, A.O.M., Morriss-Kay, G.M., Jones, E.Y. & Heath, J.K. Functions of fibroblast growth factors and their receptors. Curr. Biol. 5, 500-507 (1995).
21. Mohammadi, M., Dikic, I., Sorokin, A., Burgess, W.H., Jaye, M. & Schlessinger, J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell. Biol. 16, 977-989 (1998).
22. Hanks, S.K., Quinn, A.M. & Hunter, T. The protein kinase family: conserved features and deduced phytogeny of the catalytic domains. Science 241, 42-52 (1988).
23. Formisano, P. et al. Mutation in a conserved motif next to the insulin receptor key autophosphorylation sites de-regulates kinase activity and impairs insulin action. J. Biol. Chem. 268, 5241-5248. (1993).
24. Hubbard, S.R., Wei, L., Ellis, L. & Hendrickson, W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754. (1994).
25. Hanneken, A., Ying, W., Ling, N. & Baird, A. Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc. Natl. Acad. Sci. USA 91, 9170-9174. (1994).
26. Rupp, R.A.W., Snider, L. & Weintraub, H. Xenopus embryos regulate the nuclear localization of XMyoD. Genes Dev. 8, 1311-1323. (1994).
27. Olwin, B.B. & Hauschka, S.D. Fibroblast growth factor receptor levels decrease during chick embryogenesis. J. Cell Biol. 110, 503-509 (1990).
28. Webster, M.K. & Donoghue, D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15, 520-527 (1996).
29. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12, 390-397 (1996).
30. Deng, C., Wynshaw-Boris, A, Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921 (1996).